As the House prepared to vote on
a new version of the 21st Century Cures Act, IDSA wrote in support
and highlighted the provisions addressing antibiotic R&D, the future
research workforce, and the opioid epidemic as essential.
Funded by NIAID, the Antibacterial Resistance Leadership Group (ARLG) is tasked with prioritizing, designing, implementing, and conducting clinical studies to address antibacterial resistance. This CID article outlines resources and opportunities for clinical research, and encourages submissions of proposals. (2014)
1300 Wilson Boulevard Suite 300 Arlington, VA 22209 | Phone: (703) 299-0200 | Fax: (703) 299-0204
| HIVMA | Contact Us
© Copyright IDSA 2017 Infectious Diseases Society of America